Bosentan and the endothelin system in congestive heart failure
- 1 November 2000
- journal article
- review article
- Published by Wiley in Clinical Cardiology
- Vol. 23 (11) , 803-807
- https://doi.org/10.1002/clc.4960231128
Abstract
The endothelin system appears to play an important role in the pathophysiology of congestive heart failure (CHF). Endothelin receptor antagonists represent a novel class of agents that are being evaluated for their potential benefits in treating various cardiovascular disorders. Bosentan is an orally active endothelin receptor antagonist that has been studied for the treatment of CHF. Early clinical experience with bosentan has confirmed some benefits on hemodynamic parameters in patients with CHF. Its role in slowing the progression of the disease and improving survival remains to be elucidated.Keywords
This publication has 64 references indexed in Scilit:
- The pharmacology of bosentanExpert Opinion on Investigational Drugs, 1998
- Endothelins and endothelin receptor antagonists: Binding to plasma proteinsLife Sciences, 1996
- Deoxycorticosterone Acetate Plus Salt Induces Overexpression of Vascular Endothelin-1 and Severe Vascular Hypertrophy in Spontaneously Hypertensive RatsHypertension, 1995
- Termination of endothelin signaling: Role of nitric oxideJournal of Cellular Physiology, 1994
- ETA and ETB Receptors Coexist on Rabbit Pulmonary Artery Vascular Smooth Muscle Mediating ContractionBiochemical and Biophysical Research Communications, 1993
- Potential role of endothelin in hypertension. Controversy on endothelin in hypertension.Hypertension, 1993
- Peptide Vasoconstrictors, Vessel Structure, and Vascular Smooth-Muscle ProliferationJournal of Cardiovascular Pharmacology, 1993
- Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptorNature, 1990
- Cloning and expression of a cDNA encoding an endothelin receptorNature, 1990
- Effects of endothelin on renal hemodynamics and excretory functions in anesthetized dogsLife Sciences, 1990